Survodutide is an experimental once-weekly injection from Boehringer Ingelheim that hits two targets at once: the GLP-1 receptor (the appetite pathway behind Ozempic and Wegovy) and the glucagon receptor (which nudges the body to burn more energy and clear fat from the liver). In its big 2026 phase 3 trial it produced up to 16.6% weight loss, but the number that turned heads was a different one — a reported 63% cut in liver fat.
It is not approved anywhere, and it is not available in Canada. Here is what survodutide actually is, what the trials showed, and how it fits next to retatrutide and the other next-generation weight-loss drugs.
What survodutide is
If you have been following the obesity-drug race, you already know the pattern: every new contender adds a hormone to the GLP-1 base that made Ozempic famous. Tirzepatide added GIP. Retatrutide added GIP and glucagon. CagriSema added amylin. Survodutide takes a cleaner, two-target approach — GLP-1 plus glucagon, and nothing else.
It is a once-weekly injectable peptide developed by Boehringer Ingelheim (partnered with Zealand Pharma), and it is being studied for two big problems at the same time: obesity and a serious liver disease called MASH (metabolic dysfunction-associated steatohepatitis, the condition formerly known as NASH). That dual focus is the whole point of the molecule, and it is what makes survodutide different from the drugs built purely for the scale.
Most of the new weight-loss drugs are chasing a bigger number on the scale. Survodutide is chasing the liver too — and that might end up being the more valuable target.The case for survodutide, in one sentence
A quick, important line before we go further: survodutide is investigational. It has not been approved by the FDA, Health Canada, or any other regulator, and you cannot get it by prescription. Everything below is about what the research shows, not a product you can buy or use.
How it works (GLP-1 plus glucagon)
Survodutide is a dual agonist. “Agonist” just means it switches a receptor on. It switches on two:
- The GLP-1 receptor. This is the familiar one. Activating it slows stomach emptying, reduces appetite and improves blood-sugar control. It is the mechanism behind semaglutide (Ozempic, Wegovy) and the shared backbone of nearly every drug in this class. If you want the family tree, our retatrutide vs tirzepatide vs semaglutide guide lays it out.
- The glucagon receptor. This is the interesting one. Glucagon is best known for raising blood sugar, but activating its receptor also increases energy expenditure — roughly, the body spends more fuel — and drives the liver to break down stored fat. That is why a glucagon arm is attractive for both weight loss and fatty-liver disease.
Think of GLP-1 as the brake on how much you eat, and glucagon as the accelerator on how much you burn. Survodutide presses both. Retatrutide does the same two things and adds a third (GIP); survodutide keeps it to two, which is part of why its weight-loss numbers are a notch below retatrutide’s but its liver results are so striking.
What the trials showed
The headline readout came on April 30, 2026, from the phase 3 obesity trial SYNCHRONIZE-1.
- Weight loss: up to 16.6% at 76 weeks, versus 3.2% on placebo, in adults with obesity who did not have type 2 diabetes.
- Design: the trial used a flexible dose-escalation approach, and the top result came from the highest dose group.
A 16.6% average is a strong result — comparable to what injectable semaglutide delivers — though it sits below tirzepatide’s ~20% and retatrutide’s low-20s figures. On weight loss alone, survodutide is a strong player rather than the outright leader. But weight was never the only story.
The liver-fat story
This is where survodutide stands apart. Around June 2026, Boehringer reported a pre-specified analysis with two numbers that matter enormously for metabolic health:
- A 34% reduction in visceral fat — the dangerous fat packed around the organs, not the fat you pinch.
- A 63% reduction in liver fat, while, the company said, “minimizing lean mass loss.”
A 63% drop in liver fat is not a cosmetic result. Fatty liver is one of the fastest-growing causes of liver disease in the world, and most people who have it do not know.Why the liver numbers matter
Survodutide is being studied specifically for MASH (the LIVERAGE trials, reading out later in 2026), a condition where fat builds up in the liver and drives inflammation and scarring. There are very few good treatments. A drug that both takes off significant body weight and dramatically cuts liver fat could matter for a group of patients that current weight-loss drugs do not specifically target. That is the real pitch for survodutide, and it is why it is worth knowing about even though its scale number is not the biggest.
Who survodutide is really for
This is where survodutide’s strategy becomes clear, and it is not “everyone who wants to lose weight.” The drugs winning the obesity race on raw numbers — tirzepatide, retatrutide, CagriSema — are competing for the general weight-loss market. Survodutide is quietly aiming at a sicker, more specific group: people whose excess weight has started damaging their liver.
That group is enormous and mostly undiagnosed. Fatty liver disease tracks closely with obesity and type 2 diabetes, and MASH — the inflammatory, scarring form — can progress silently for years before causing symptoms. Until recently there was almost nothing to offer these patients beyond “lose weight,” which is exactly the thing they struggle to do. A single weekly injection that both drops body weight and slashes liver fat would be a genuinely new tool, not just another entry in a crowded weight-loss aisle.
So when you see survodutide’s 16.6% and think “that’s less than retatrutide,” you are measuring it on the wrong axis. Its real competitors are not the obesity blockbusters; they are the handful of liver-disease drugs in development. On that scoreboard, its numbers look very different.
Side effects and tolerability
Like every drug in this family, survodutide’s most common side effects are gastrointestinal: nausea, vomiting and diarrhea, usually worst during dose escalation and easing over time. These are the same complaints people report on Ozempic, Zepbound and the rest.
The glucagon arm adds a specific thing to watch. Because glucagon affects blood sugar and heart rate, drugs that activate its receptor get extra scrutiny on those fronts, and tolerability at the highest, most effective doses is a key question for the whole glucagon-agonist category — survodutide and retatrutide alike. As an investigational drug, survodutide’s long-term human safety is simply not yet established. None of this is medical advice; it is a summary of what the trials are reporting.
How it compares to retatrutide and CagriSema
Here is the quick side-by-side of the three big non-tirzepatide contenders, using each drug’s own trial data. Remember these come from separate trials, so the comparison is directional, not head-to-head.
| Drug | Targets | Top weight loss | Standout feature |
|---|---|---|---|
| Survodutide | GLP-1 + glucagon | ~16.6% (SYNCHRONIZE-1) | 63% liver-fat reduction; MASH focus |
| Retatrutide | GIP + GLP-1 + glucagon | ~20.8–22.6% (TRIUMPH) | Largest weight-loss numbers so far |
| CagriSema | Amylin + GLP-1 | ~22.7% (REDEFINE 1) | Nearest to a regulatory decision |
The takeaway: retatrutide and CagriSema are competing to be the biggest scale-mover, while survodutide is carving out the metabolic-liver lane. We compare the first two directly in CagriSema vs retatrutide, and track the whole pipeline in the next weight-loss drugs after Ozempic.
Status in Canada
Survodutide is not approved in Canada, not sold at pharmacies, and not something you can be prescribed as of October 2026. It is in clinical trials, full stop.
It is worth repeating the regulatory reality for this whole category in Canada: Health Canada’s April 2026 advisory was explicit that injectable peptides are generally prescription drugs, that unauthorized products sold online are illegal, and that a “research use only” label gives no exemption. Research-grade material sold for laboratory use is a separate category that is not for human use. If you are following survodutide for a personal health reason — obesity or fatty-liver disease — the right next step is a conversation with your doctor about the approved options that exist today, which we touch on in generic Ozempic in Canada.
Survodutide myths
“Myth: Survodutide is weaker, so it doesn’t matter.”
Its weight-loss number is a notch below retatrutide’s, but its liver-fat and visceral-fat results are its reason to exist. For MASH and metabolic health, that could make it more relevant than a drug that only moves the scale.
“Myth: It’s basically the same as retatrutide.”
Both use a glucagon arm, but retatrutide is a triple agonist (it adds GIP) and survodutide is a dual agonist. Different design, different balance of effects, different lead indication (retatrutide for obesity; survodutide with a heavy MASH focus).
“Myth: You can buy survodutide now.”
No. It is investigational and not approved or sold anywhere. Anything marketed online under that name is not a regulated medicine, and in Canada selling it for human use is illegal.
“Myth: The 63% liver-fat number means it reverses liver disease.”
Cutting liver fat is promising, but reversing established scarring (fibrosis) is a harder, separate question. The dedicated MASH trials are what will answer whether the liver-fat drop translates into real disease benefit.
For researchers
Survodutide itself is not a research-catalogue compound — it is a proprietary investigational drug. If your interest is the underlying pharmacology (incretin and glucagon-receptor signalling, metabolic models), TrueLabs supplies related reference peptides in CAD, for in vitro and laboratory research only, never for human or veterinary use, including RT3 (retatrutide) from $90, TZ-2 (tirzepatide) from $73 and cagrilintide from $40. Before ordering, see how to read a peptide COA and the COA library.
FAQ
Tap a question to reveal the answer.
What is survodutide?
Survodutide is an experimental once-weekly injectable peptide from Boehringer Ingelheim and Zealand Pharma. It is a dual agonist that activates the GLP-1 and glucagon receptors, and it is being studied for both obesity and the liver disease MASH. It is not approved anywhere.
How much weight loss does survodutide produce?
In the phase 3 SYNCHRONIZE-1 trial (reported April 2026), survodutide produced up to 16.6% weight loss at 76 weeks versus 3.2% on placebo, in adults with obesity without type 2 diabetes. That is comparable to injectable semaglutide and below tirzepatide and retatrutide.
What makes survodutide different from other weight-loss drugs?
Its dual GLP-1/glucagon design and its strong effect on the liver. A pre-specified analysis reported a 63% reduction in liver fat and a 34% reduction in visceral fat, and the drug is being developed specifically for MASH, a fatty-liver disease with few treatments.
Is survodutide better than retatrutide?
Not on weight loss — retatrutide reported larger figures (low-20s percent). Survodutide’s advantage is its liver and visceral-fat results and its MASH focus. They are built for somewhat different goals, so “better” depends on what you are measuring.
Is survodutide approved in Canada?
No. It is investigational, not approved by Health Canada, and not available by prescription or at pharmacies. It is only in clinical trials as of October 2026.
What is MASH, and why does survodutide target it?
MASH (metabolic dysfunction-associated steatohepatitis) is a liver disease where fat buildup drives inflammation and scarring. There are few effective treatments. Survodutide’s glucagon arm cuts liver fat substantially, which is why it is in dedicated MASH trials (LIVERAGE) alongside its obesity programme.
What are survodutide’s side effects?
Like other drugs in the class, mainly gastrointestinal: nausea, vomiting and diarrhea, usually during dose escalation. Because of the glucagon arm, blood-sugar and heart-rate effects get extra scrutiny. Long-term human safety is not yet established.
Can I buy survodutide for research?
Survodutide is a proprietary investigational drug, not a standard research-catalogue peptide. Related reference compounds like retatrutide and tirzepatide are sold for laboratory research use only, never for human use.
When could survodutide be approved?
There is no approval date. Its obesity and MASH trials are still reading out through and beyond 2026, and any regulatory filing and review would follow those. Treat any specific “launch date” claim with skepticism.
Related reading
- CagriSema vs retatrutide
- What is retatrutide?
- Retatrutide vs tirzepatide vs semaglutide
- The next weight-loss drugs after Ozempic
- Retatrutide phase 3 results
References
- Boehringer Ingelheim. SYNCHRONIZE-1 phase 3 topline: survodutide delivers up to 16.6% weight loss (April 30, 2026). PharmaTimes. PharmaTimes
- Boehringer Ingelheim. Survodutide reduces visceral (34%) and liver (63%) fat in pre-specified phase 3 analysis. BioPharm International. BioPharm International
- Health Canada. Think twice before injecting peptides bought online (advisory, April 9, 2026). Health Canada recalls and safety alerts
This article summarizes published research and regulatory information for information only and is not medical advice. TrueLabs research compounds are sold for in vitro and laboratory research use only and are not intended for human or veterinary use.